Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for Kamic Electronics in connection with the public offer for ElektronikGruppen
Mandate

Vinge acts for Kamic Electronics in connection with the public offer for ElektronikGruppen

June 22, 2011

Kamic Electronics has announced a public cash offer for ElektronikGruppen BK Aktiebolag (publ) (”ElektronikGruppen”). The class B shares of Eletronikgruppen are listed on NASDAQ OMX Stockholm. The offer is conducted in accordance with the NASDAQ OMX Stockholm’s rules regarding MBO offers.

Vinge acts for Kamic Electronics. Vinge’s team is headed by Rikard Stenberg and includes Johan Thiman (public M&A) and, with respect to the bankfinancing of the offer, Maria-Pia Hope and Anders Morén. In addition, Viges team comprises Lennart Larsson (tax) och Peter Alstergren (merger control). ABG Sundal Collier acts as financial advisor to the offeror.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024